Close

BIO Applauds House Passage of the Corporate Governance Reform and Transparency Act

Dec 21 2017
Washington, DC (December 21, 2017) – Today, the Biotechnology Innovation Organization (BIO) applauds the House of Representatives for passing H.R. 4015, the Corporate Governance Reform and Transparency Act.  This bipartisan bill, sponsored by Reps. Sean Duffy (R-WI) and Gregory Meeks (D-NY), was approved by a 238-182 vote.

BIO Applauds USTR for Standing Up for Ag Innovation and Sound Science

Dec 14 2017
U.S. Government and 16 like-minded WTO Members Call for Implementation of the Sanitary and Phytosanitary (SPS) Agreement Washington, D.C. (December 14, 2017) – The Biotechnology Innovation Organization (BIO) is applauding efforts by the United States Government and other World Trade Organization (WTO) members for committing to strengthen the implementation and application of Sanitary and Phytosanitary Measures (SPS Agreement).  

Dynamic Speaker Lineup Announced for BIO CEO & Investor Conference

Dec 14 2017
The Biotechnology Innovation Organization (BIO) today announces preliminary programing for the upcoming BIO CEO & Investor Conference to be held February 12-13, 2018 in New York. The program will include a diverse group of industry luminaries at the forefront of exciting science in such areas as gene therapy and new oncology treatments.

2018 RFS Volumes Set Back Growth in Cellulosic Biofuels

Nov 30 2017
BIO is disappointed that EPA did not raise the Renewable Fuel Standard's advanced and cellulosic biofuel volumes for 2018 in line with the industry’s ability to produce them.

BIO Applauds Sens. Tillis and Peters for Introducing the Fostering Innovation Act

Nov 15 2017
Washington, DC (November 15, 2017) – Today, the Biotechnology Innovation Organization (BIO) applauds Sens. Thom Tillis (R-NC) and Gary Peters (D-MI) for introducing the Fostering Innovation Act.  This vital legislation would build on the success of the JOBS Act and further reduce regulatory costs for biotech small businesses.

BIO Statement on Senate GOP Tax Reform Proposal

Nov 10 2017
Washington, DC (November 10, 2017) – Biotechnology Innovation Organization (BIO) Senior Vice President of Communications Kenneth Lisaius released the following statement regarding the Senate GOP tax reform proposal.

BIO Statement on USDA Withdrawal of 340 Biotech Rules

Nov 6 2017
The U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) today announced its intention to withdraw its proposed revisions to regulations (7 CFR part 340) governing agricultural biotechnology.  The Biotechnology Innovation Organization (BIO) issued the following statement in response:

BIO Releases Plan to Unleash Innovation in Fight against Opioid Abuse and Addiction

Nov 2 2017
Washington, DC (November 2, 2017) – The Biotechnology Innovation Organization (BIO) today released a set of priorities for unleashing the power of innovation to develop solutions to prescription opioid abuse and addiction. Many of BIO’s priorities align with recommendations put forth yesterday by the President’s Commission on Combating Drug Addiction and the Opioid Crisis, including proposals to ensure that patients have comprehensive access to appropriate treatments, and increasing support for basic research to improve our understanding of the biology of pain and addiction. 

BIO Statement on House GOP Tax Reform Bill

Nov 2 2017
Washington, DC (November 2, 2017) – Biotechnology Innovation Organization (BIO) Jim Greenwood released the following statement today regarding the Tax Cuts and Jobs Act: “BIO applauds Chairman Brady and the House Ways & Means Committee for their dedication to pro-growth tax reform. Tax reform presents a unique, historic opportunity to stimulate American investment, support job creation, and promote life-saving innovation. The Tax Cuts and Jobs Act would lower America’s corporate tax rate, maintain the R&D Tax Credit, and move the U.S. to a territorial tax system, which will make the U.S. more competitive on the world stage and support domestic manufacturing and job creation. This reform is vital to maintaining American leadership in biotechnology innovation.

BIO Applauds MLP Parity Act, Thanks Senate and House Sponsors

Oct 25 2017
The bipartisan Master Limited Partnerships Parity Act of 2017 would level the playing field in the tax code by giving investors in renewable energy projects access to a decades-old corporate structure with a tax advantage now available only to fossil fuel projects.